Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 280

1.

Definition of synchronous oligo-metastatic non-small cell lung cancer - a consensus report.

Dingemans AC, Hendriks LEL, Berghmans T, Levy A, Hasan B, Faivre-Finn C, Giaj-Levra M, Giaj-Levra N, Girard N, Greillier L, Lantuéjoul S, Edwards J, O'Brien M, Reck M, Smit EF, Van Schil P, Postmus PE, Ramella S, Lievens Y, Gaga M, Peled N, Scagliotti GV, Senan S, Paz-Ares L, Guckenberger M, McDonald F, Ekman S, Cufer T, Gietema H, Infante M, Dziadziuszko R, Peters S, Porta RR, Vansteenkiste J, Dooms C, de Ruysscher D, Besse B, Novello S.

J Thorac Oncol. 2019 Aug 6. pii: S1556-0864(19)30655-0. doi: 10.1016/j.jtho.2019.07.025. [Epub ahead of print]

PMID:
31398540
2.

Impact of Heat Shock Protein 90 Inhibition on the Proteomic Profile of Lung Adenocarcinoma as Measured by Two-Dimensional Electrophoresis Coupled with Mass Spectrometry.

Marrugal Á, Ferrer I, Pastor MD, Ojeda L, Quintanal-Villalonga Á, Carnero A, Molina-Pinelo S, Paz-Ares L.

Cells. 2019 Jul 31;8(8). pii: E806. doi: 10.3390/cells8080806.

3.

Treatment options beyond immunotherapy in patients with wild-type lung adenocarcinoma: a Delphi consensus.

Isla D, de Castro J, García-Campelo R, Lianes P, Felip E, Garrido P, Paz-Ares L, Trigo JM.

Clin Transl Oncol. 2019 Jul 31. doi: 10.1007/s12094-019-02191-y. [Epub ahead of print]

PMID:
31368078
4.

Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Non-Small Cell Lung Carcinoma Patients: the ROSING Study.

Conde E, Hernandez S, Martinez R, Angulo B, De Castro J, Collazo-Lorduy A, Jimenez B, Muriel A, Mate JL, Moran T, Aranda I, Massuti B, Rojo F, Domine M, Sansano I, Garcia F, Felip E, Mancheño N, Juan O, Sanz J, Gonzalez-Larriba JL, Atienza-Cuevas L, Arriola-Arellano E, Abdulkader I, Garcia-Gonzalez J, Camacho C, Rodriguez-Abreu D, Teixido C, Reguart N, Gonzalez-Piñeiro A, Lazaro-Quintela M, Lozano MD, Gurpide A, Gomez-Roman J, Lopez-Brea M, Pijuan L, Salido M, Arriola E, Company A, Insa A, Esteban-Rodriguez I, Saiz M, Azkona E, Alvarez R, Artal A, Plaza ML, Aguiar D, Enguita AB, Benito A, Paz-Ares L, Garrido P, Lopez-Rios F.

J Thorac Oncol. 2019 Jul 23. pii: S1556-0864(19)30562-3. doi: 10.1016/j.jtho.2019.07.005. [Epub ahead of print]

5.

Prognostic Significance of Liver Metastasis in Durvalumab-Treated Lung Cancer Patients.

Sridhar S, Paz-Ares L, Liu H, Shen K, Morehouse C, Rizvi N, Segal NH, Jin X, Zheng Y, Narwal R, Gupta A, Dennis PA, Ye J, Mukhopadhyay P, Higgs BW, Ranade K.

Clin Lung Cancer. 2019 Jun 26. pii: S1525-7304(19)30171-8. doi: 10.1016/j.cllc.2019.06.020. [Epub ahead of print]

6.

Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance.

Zugazagoitia J, Gómez-Rueda A, Jantus-Lewintre E, Isla D, Camps C, Ramos I, Trigo JM, Bernabé R, Juan-Vidal O, Sanchez-Torres JM, García-Campelo R, Provencio M, Felip E, de Castro J, Faull I, Lanman RB, Ponce-Aix S, Paz-Ares L, Garrido P.

Lung Cancer. 2019 Aug;134:72-78. doi: 10.1016/j.lungcan.2019.05.032. Epub 2019 May 30.

PMID:
31319999
7.

First-line immune checkpoint blockade for advanced non-small-cell lung cancer: Travelling at the speed of light.

Ackermann CJ, Reck M, Paz-Ares L, Barlesi F, Califano R.

Lung Cancer. 2019 Aug;134:245-253. doi: 10.1016/j.lungcan.2019.06.007. Epub 2019 Jun 19. Review.

PMID:
31319988
8.

Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.

Herbst RS, Arkenau HT, Santana-Davila R, Calvo E, Paz-Ares L, Cassier PA, Bendell J, Penel N, Krebs MG, Martin-Liberal J, Isambert N, Soriano A, Wermke M, Cultrera J, Gao L, Widau RC, Mi G, Jin J, Ferry D, Fuchs CS, Petrylak DP, Chau I.

Lancet Oncol. 2019 Aug;20(8):1109-1123. doi: 10.1016/S1470-2045(19)30458-9. Epub 2019 Jul 10.

PMID:
31301962
9.

First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials.

Schuler M, Paz-Ares L, Sequist LV, Hirsh V, Lee KH, Wu YL, Lu S, Zhou C, Feng J, Ellis SH, Samuelsen CH, Tang W, Märten A, Ehrnrooth E, Park K, Yang JC.

Lung Cancer. 2019 Jul;133:10-19. doi: 10.1016/j.lungcan.2019.04.006. Epub 2019 Apr 8.

10.

YES1 Drives Lung Cancer Growth and Progression and Predicts Sensitivity to Dasatinib.

Garmendia I, Pajares MJ, Hermida-Prado F, Ajona D, Bértolo C, Sainz C, Lavín A, Remírez AB, Valencia K, Moreno H, Ferrer I, Behrens C, Cuadrado M, Paz-Ares L, Bustelo XR, Gil-Bazo I, Alameda D, Lecanda F, Calvo A, Felip E, Sánchez-Céspedes M, Wistuba II, Granda-Diaz R, Rodrigo JP, García-Pedrero JM, Pio R, Montuenga LM, Agorreta J.

Am J Respir Crit Care Med. 2019 Jun 5. doi: 10.1164/rccm.201807-1292OC. [Epub ahead of print]

PMID:
31166114
11.

A patent review of FGFR4 selective inhibition in cancer (2007-2018).

Quintanal-Villalonga A, Ferrer I, Molina-Pinelo S, Paz-Ares L.

Expert Opin Ther Pat. 2019 May 30;29(6):429-438. doi: 10.1080/13543776.2019.1624720. Print 2019 Jun. Review.

PMID:
31146605
12.

Fra-2-expressing macrophages promote lung fibrosis in mice.

Ucero AC, Bakiri L, Roediger B, Suzuki M, Jimenez M, Mandal P, Braghetta P, Bonaldo P, Paz-Ares L, Fustero-Torre C, Ximenez-Embun P, Hernandez AI, Megias D, Wagner EF.

J Clin Invest. 2019 May 28;129(8):3293-3309. doi: 10.1172/JCI125366.

13.

Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer.

Park K, Bennouna J, Boyer M, Hida T, Hirsh V, Kato T, Lu S, Mok T, Nakagawa K, O'Byrne K, Paz-Ares L, Schuler M, Sibilot DM, Tan EH, Tanaka H, Wu YL, Yang JC, Zhang L, Zhou C, Märten A, Tang W, Yamamoto N.

Lung Cancer. 2019 Jun;132:126-131. doi: 10.1016/j.lungcan.2019.04.014. Epub 2019 Apr 10.

14.

FGFR4 increases EGFR oncogenic signaling in lung adenocarcinoma, and their combined inhibition is highly effective.

Quintanal-Villalonga A, Molina-Pinelo S, Yagüe P, Marrugal Á, Ojeda-Márquez L, Suarez R, Ponce-Aix S, Enguita AB, Carnero A, Ferrer I, Paz-Ares L.

Lung Cancer. 2019 May;131:112-121. doi: 10.1016/j.lungcan.2019.02.007. Epub 2019 Feb 8.

PMID:
31027687
15.

Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts.

Putora PM, Glatzer M, De Ruysscher D, Faivre-Finn C, Belderbos J, Besse B, Blackhall F, Califano R, Cappuzzo F, de Marinis F, Dziadiuszko R, Felip E, Früh M, Garrido P, Le Pechoux C, McDonald F, Nestle U, Novello S, Brien MO, Paz Ares L, Peeters S, Pöttgen S, Ramella S, Reck M, Troost EGC, Van Houtte P, Westeel V, Widder J, Mornex F, Slotman BJ.

Radiother Oncol. 2019 Jun;135:74-77. doi: 10.1016/j.radonc.2019.02.010. Epub 2019 Mar 15.

PMID:
31015173
16.

Prophylactic cranial irradiation in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts.

Putora PM, Glatzer M, Belderbos J, Besse B, Blackhall F, Califano R, Cappuzzo F, de Marinis F, Dziadziuszko R, Felip E, Faivre-Finn C, Früh M, Garrido P, Le Pechoux C, McDonald F, Nestle U, Novello S, O'Brien M, Paz Ares L, Peeters S, Pöttgen C, Ramella S, Reck M, Slotman B, Troost EGC, Van Houtte P, Westeel V, Widder J, Mornex F, De Ruysscher D.

Radiother Oncol. 2019 Apr;133:163-166. doi: 10.1016/j.radonc.2018.12.014. Epub 2019 Jan 31.

PMID:
30935574
17.

Afatinib With Pembrolizumab for Treatment of Patients With Locally Advanced/Metastatic Squamous Cell Carcinoma of the Lung: The LUX-Lung IO/KEYNOTE 497 Study Protocol.

Levy B, Paz-Ares L, Bennouna J, Felip E, Abreu DR, Isla D, Barlesi F, Molinier O, Madelaine J, Audigier-Valette C, Kim SW, Kim HR, Ozguroglu M, Erman M, Badin FB, Mekhail TM, Scheff R, Chisamore MJ, Sadrolhefazi B, Riess JW.

Clin Lung Cancer. 2019 May;20(3):e407-e412. doi: 10.1016/j.cllc.2018.12.022. Epub 2019 Jan 4.

18.

First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers.

Ready N, Hellmann MD, Awad MM, Otterson GA, Gutierrez M, Gainor JF, Borghaei H, Jolivet J, Horn L, Mates M, Brahmer J, Rabinowitz I, Reddy PS, Chesney J, Orcutt J, Spigel DR, Reck M, O'Byrne KJ, Paz-Ares L, Hu W, Zerba K, Li X, Lestini B, Geese WJ, Szustakowski JD, Green G, Chang H, Ramalingam SS.

J Clin Oncol. 2019 Apr 20;37(12):992-1000. doi: 10.1200/JCO.18.01042. Epub 2019 Feb 20.

PMID:
30785829
19.

First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression.

Schuler M, Tan EH, O'Byrne K, Zhang L, Boyer M, Mok T, Hirsh V, Yang JC, Lee KH, Lu S, Shi Y, Kim SW, Laskin J, Kim DW, Arvis CD, Kölbeck K, Massey D, Märten A, Paz-Ares L, Park K.

J Cancer Res Clin Oncol. 2019 Jun;145(6):1569-1579. doi: 10.1007/s00432-019-02862-x. Epub 2019 Feb 19.

20.

Defining aggressive or early progressing nononcogene-addicted non-small-cell lung cancer: a separate disease entity?

Reck M, Kerr KM, Grohé C, Manegold C, Pavlakis N, Paz-Ares L, Huber RM, Popat S, Thatcher N, Park K, Hilberg F, Barrueco J, Kaiser R.

Future Oncol. 2019 Apr;15(12):1363-1383. doi: 10.2217/fon-2018-0948. Epub 2019 Feb 13. Review.

21.

Safety of eribulin as third-line chemotherapy in HER2-negative, advanced breast cancer pre-treated with taxanes and anthracycline: OnSITE study.

Manso L, Moreno Antón F, Izarzugaza Perón Y, Delgado Mingorance JI, Borrega García P, Echarri González MJ, Martínez-Jañez N, López-González A, Olier Garate C, Ballesteros García A, Chacón López-Muñíz I, Ciruelos Gil E, García-Sáenz JA, Paz-Ares L.

Breast J. 2019 Mar;25(2):219-225. doi: 10.1111/tbj.13199. Epub 2019 Feb 8.

PMID:
30734437
22.

Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer.

Levy BP, Giaccone G, Besse B, Felip E, Garassino MC, Domine Gomez M, Garrido P, Piperdi B, Ponce-Aix S, Menezes D, MacBeth KJ, Risueño A, Slepetis R, Wu X, Fandi A, Paz-Ares L.

Eur J Cancer. 2019 Feb;108:120-128. doi: 10.1016/j.ejca.2018.11.028. Epub 2019 Jan 14.

PMID:
30654297
23.

FGFR1 Cooperates with EGFR in Lung Cancer Oncogenesis, and Their Combined Inhibition Shows Improved Efficacy.

Quintanal-Villalonga A, Molina-Pinelo S, Cirauqui C, Ojeda-Márquez L, Marrugal Á, Suarez R, Conde E, Ponce-Aix S, Enguita AB, Carnero A, Ferrer I, Paz-Ares L.

J Thorac Oncol. 2019 Apr;14(4):641-655. doi: 10.1016/j.jtho.2018.12.021. Epub 2019 Jan 9.

24.

Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP).

Peters S, Dafni U, Boyer M, De Ruysscher D, Faivre-Finn C, Felip E, Garrido P, Girard N, Guckenberger M, Haanen J, Le Pechoux C, Mornex F, Ozsahin M, Paz-Ares L, Planchard D, Raben D, Ramalingam S, Reck M, Smit E, Stahel R, Stenzinger A, Swanton C, Vallone S, Garassino MC.

Ann Oncol. 2019 Feb 1;30(2):161-165. doi: 10.1093/annonc/mdy553. No abstract available.

PMID:
30624547
25.

Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping.

Zugazagoitia J, Ramos I, Trigo JM, Palka M, Gómez-Rueda A, Jantus-Lewintre E, Camps C, Isla D, Iranzo P, Ponce-Aix S, García-Campelo R, Provencio M, Franco F, Bernabé R, Juan-Vidal O, Felip E, de Castro J, Sanchez-Torres JM, Faul I, Lanman RB, Garrido P, Paz-Ares L.

Ann Oncol. 2019 Feb 1;30(2):290-296. doi: 10.1093/annonc/mdy512.

PMID:
30535340
26.

Necitumumab for the treatment of advanced non-small-cell lung cancer.

Díaz-Serrano A, Sánchez-Torre A, Paz-Ares L.

Future Oncol. 2019 Mar;15(7):705-716. doi: 10.2217/fon-2018-0594. Epub 2018 Dec 3. Review.

PMID:
30501503
27.

Enhanced Cytotoxic Activity of Mitochondrial Mechanical Effectors in Human Lung Carcinoma H520 Cells: Pharmaceutical Implications for Cancer Therapy.

González Rubio S, Montero Pastor N, García C, Almendro-Vedia VG, Ferrer I, Natale P, Paz-Ares L, Lillo MP, López-Montero I.

Front Oncol. 2018 Nov 13;8:514. doi: 10.3389/fonc.2018.00514. eCollection 2018.

28.

Pemetrexed Continuation Maintenance Phase 3 Trials in Nonsquamous, Non-Small-Cell Lung Cancer: Focus on 2-Year Overall Survival and Continuum of Care.

Patel JD, Paz-Ares L, Zinner RG, Barlesi F, Koustenis AG, Obasaju CK.

Clin Lung Cancer. 2018 Nov;19(6):e823-e830. doi: 10.1016/j.cllc.2018.05.013. Epub 2018 May 26. Review.

PMID:
30369427
29.

ATLANTIS: a Phase III study of lurbinectedin/doxorubicin versus topotecan or cyclophosphamide/doxorubicin/vincristine in patients with small-cell lung cancer who have failed one prior platinum-containing line.

Farago AF, Drapkin BJ, Lopez-Vilarino de Ramos JA, Galmarini CM, Núñez R, Kahatt C, Paz-Ares L.

Future Oncol. 2019 Jan;15(3):231-239. doi: 10.2217/fon-2018-0597. Epub 2018 Oct 26.

PMID:
30362375
30.

Durvalumab in NSCLC: latest evidence and clinical potential.

Muñoz-Unceta N, Burgueño I, Jiménez E, Paz-Ares L.

Ther Adv Med Oncol. 2018 Oct 11;10:1758835918804151. doi: 10.1177/1758835918804151. eCollection 2018. Review.

31.

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.

Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeño J, Faivre-Finn C, Reck M, Vansteenkiste J, Spigel DR, Wadsworth C, Melillo G, Taboada M, Dennis PA, Özgüroğlu M; PACIFIC Investigators.

N Engl J Med. 2018 Dec 13;379(24):2342-2350. doi: 10.1056/NEJMoa1809697. Epub 2018 Sep 25.

PMID:
30280658
32.

Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.

Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, Hermes B, Çay Şenler F, Csőszi T, Fülöp A, Rodríguez-Cid J, Wilson J, Sugawara S, Kato T, Lee KH, Cheng Y, Novello S, Halmos B, Li X, Lubiniecki GM, Piperdi B, Kowalski DM; KEYNOTE-407 Investigators.

N Engl J Med. 2018 Nov 22;379(21):2040-2051. doi: 10.1056/NEJMoa1810865. Epub 2018 Sep 25.

33.

KRAS-Mutant non-small cell lung cancer: From biology to therapy.

Ferrer I, Zugazagoitia J, Herbertz S, John W, Paz-Ares L, Schmid-Bindert G.

Lung Cancer. 2018 Oct;124:53-64. doi: 10.1016/j.lungcan.2018.07.013. Epub 2018 Jul 19. Review.

34.

Lung Cancer with a High Tumor Mutational Burden.

Hellmann MD, Paz-Ares L.

N Engl J Med. 2018 Sep 13;379(11):1093-1094. doi: 10.1056/NEJMc1808566. No abstract available.

PMID:
30207915
35.

MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinoma.

Ferrer I, Quintanal-Villalonga Á, Molina-Pinelo S, Garcia-Heredia JM, Perez M, Suárez R, Ponce-Aix S, Paz-Ares L, Carnero A.

J Exp Clin Cancer Res. 2018 Aug 17;37(1):195. doi: 10.1186/s13046-018-0871-7.

36.

Corrigendum to "Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical Implications".

Quintanal-Villalonga A, Paz-Ares L, Ferrer I, Molina-Pinelo S.

Dis Markers. 2018 Jul 19;2018:3714684. doi: 10.1155/2018/3714684. eCollection 2018.

37.

Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non-Small Cell Lung Cancer: A Phase Ib Study.

Kim ES, Kelly K, Paz-Ares LG, Garrido P, Jalal S, Mahadevan D, Gutierrez M, Provencio M, Schaefer E, Shaheen M, Johnston EL, Turner PK, Kambhampati SRP, Beckmann R, Hossain A, John WJ, Goldman JW.

Clin Cancer Res. 2018 Nov 15;24(22):5543-5551. doi: 10.1158/1078-0432.CCR-18-0651. Epub 2018 Aug 6.

PMID:
30082474
38.

Corrigendum to "Proteomic-Based Approaches for the Study of Cytokines in Lung Cancer".

Marrugal Á, Ojeda L, Paz-Ares L, Molina-Pinelo S, Ferrer I.

Dis Markers. 2018 Jul 8;2018:1404780. doi: 10.1155/2018/1404780. eCollection 2018.

39.

30 Immunotherapy in advanced NSCLC-from the 'tsunami' of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT).

de Marinis F, Ciardiello F, Baas P, Crinò L, Giaccone G, Grossi F, Hellmann MD, Mok TSK, Lena H, Paz-Ares L, Rodriguez-Abreu D, Von Pavel J, Gridelli C.

ESMO Open. 2018 May 31;3(4):e000298. doi: 10.1136/esmoopen-2017-000298. eCollection 2018. Review.

40.

Cancer immunotherapy: Great expectations in the world of oncology but a cause for kidney concern.

Redondo B, Moliz C, Alonso M, Paz-Ares L, Praga M, Morales E.

Nefrologia. 2019 Jan - Feb;39(1):94-96. doi: 10.1016/j.nefro.2018.05.002. Epub 2018 Jun 23. English, Spanish. No abstract available.

41.

Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer.

Bonomi PD, Gandara D, Hirsch FR, Kerr KM, Obasaju C, Paz-Ares L, Bellomo C, Bradley JD, Bunn PA Jr, Culligan M, Jett JR, Kim ES, Langer CJ, Natale RB, Novello S, Pérol M, Ramalingam SS, Reck M, Reynolds CH, Smit EF, Socinski MA, Spigel DR, Vansteenkiste JF, Wakelee H, Thatcher N.

Ann Oncol. 2018 Aug 1;29(8):1701-1709. doi: 10.1093/annonc/mdy196.

42.

Venous thromboembolism with EGFR monoclonal antibody necitumumab in stage IV non-small cell lung cancer: A retrospective cohort analysis.

Young K, Paz-Ares L, Thatcher N, Spigel DR, Shahidi J, Soldatenkova V, Grau G, Kurek R, Shepherd FA.

Thromb Res. 2018 Jul;167:50-56. doi: 10.1016/j.thromres.2018.05.004. Epub 2018 May 7.

PMID:
29787943
43.

Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies.

Hirsch FR, Kerr KM, Bunn PA Jr, Kim ES, Obasaju C, Pérol M, Bonomi P, Bradley JD, Gandara D, Jett JR, Langer CJ, Natale RB, Novello S, Paz-Ares L, Ramalingam SS, Reck M, Reynolds CH, Smit EF, Socinski MA, Spigel DR, Stinchcombe TE, Vansteenkiste JF, Wakelee H, Thatcher N.

Clin Lung Cancer. 2018 Jul;19(4):331-339. doi: 10.1016/j.cllc.2018.03.014. Epub 2018 Mar 21. Review.

44.

Histology-dependent prognostic role of pERK and p53 protein levels in early-stage non-small cell lung cancer.

Quintanal-Villalonga Á, Mediano M, Ferrer I, Meléndez R, Carranza-Carranza A, Suárez R, Carnero A, Molina-Pinelo S, Paz-Ares L.

Oncotarget. 2018 Apr 13;9(28):19945-19960. doi: 10.18632/oncotarget.24977. eCollection 2018 Apr 13.

45.

Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with Trastuzumab.

Díaz-Serrano A, Angulo B, Dominguez C, Pazo-Cid R, Salud A, Jiménez-Fonseca P, Leon A, Galan MC, Alsina M, Rivera F, Plaza JC, Paz-Ares L, Lopez-Rios F, Gómez-Martín C.

Oncologist. 2018 Sep;23(9):1092-1102. doi: 10.1634/theoncologist.2017-0379. Epub 2018 Apr 26.

PMID:
29700210
46.

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.

Hellmann MD, Ciuleanu TE, Pluzanski A, Lee JS, Otterson GA, Audigier-Valette C, Minenza E, Linardou H, Burgers S, Salman P, Borghaei H, Ramalingam SS, Brahmer J, Reck M, O'Byrne KJ, Geese WJ, Green G, Chang H, Szustakowski J, Bhagavatheeswaran P, Healey D, Fu Y, Nathan F, Paz-Ares L.

N Engl J Med. 2018 May 31;378(22):2093-2104. doi: 10.1056/NEJMoa1801946. Epub 2018 Apr 16.

47.

Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials.

Wu YL, Sequist LV, Tan EH, Geater SL, Orlov S, Zhang L, Lee KH, Tsai CM, Kato T, Barrios CH, Schuler M, Hirsh V, Yamamoto N, O'Byrne K, Boyer M, Mok T, Peil B, Märten A, Chih-Hsin Yang J, Paz-Ares L, Park K.

Clin Lung Cancer. 2018 Jul;19(4):e465-e479. doi: 10.1016/j.cllc.2018.03.009. Epub 2018 Mar 17.

48.

Incidence, predictors and prognostic significance of thromboembolic disease in patients with advanced ALK-rearranged non-small cell lung cancer.

Zugazagoitia J, Biosca M, Oliveira J, Olmedo ME, Dómine M, Nadal E, Ruffinelli JC, Muñoz N, Luna AM, Hernández B, Martínez M, Gallego I, Martínez de Castro E, Font C, Calvo V, Martínez-Marín V, Corral J, Noguerón E, Mondéjar R, García Escobar I, Salvador-Coloma C, Juan Ó, Sánchez Cánovas M, Valdivia J, Ochoa MP, López Castro R, Obispo B, Pangua C, Sereno M, Fernández Franco L, Mielgo X, Calzas J, Blasco A, Aparisi F, Chara L, Grau JF, Soares M, Gómez A, Zenzola V, García-Morillo M, Cacho D, Díaz-Serrano A, Aguado C, Ponce-Aix S, González-Larriba JL, Muñoz AJ, Lora D, Paz-Ares L, Manzano A.

Eur Respir J. 2018 May 3;51(5). pii: 1702431. doi: 10.1183/13993003.02431-2017. Print 2018 May. No abstract available.

PMID:
29563169
49.

MyD88 and TLR4 Expression in Epithelial Ovarian Cancer.

Block MS, Vierkant RA, Rambau PF, Winham SJ, Wagner P, Traficante N, Tołoczko A, Tiezzi DG, Taran FA, Sinn P, Sieh W, Sharma R, Rothstein JH, Ramón Y Cajal T, Paz-Ares L, Oszurek O, Orsulic S, Ness RB, Nelson G, Modugno F, Menkiszak J, McGuire V, McCauley BM, Mack M, Lubiński J, Longacre TA, Li Z, Lester J, Kennedy CJ, Kalli KR, Jung AY, Johnatty SE, Jimenez-Linan M, Jensen A, Intermaggio MP, Hung J, Herpel E, Hernandez BY, Hartkopf AD, Harnett PR, Ghatage P, García-Bueno JM, Gao B, Fereday S, Eilber U, Edwards RP, de Sousa CB, de Andrade JM, Chudecka-Głaz A, Chenevix-Trench G, Cazorla A, Brucker SY; Australian Ovarian Cancer Study Group, Alsop J, Whittemore AS, Steed H, Staebler A, Moysich KB, Menon U, Koziak JM, Kommoss S, Kjaer SK, Kelemen LE, Karlan BY, Huntsman DG, Høgdall E, Gronwald J, Goodman MT, Gilks B, García MJ, Fasching PA, de Fazio A, Deen S, Chang-Claude J, Candido Dos Reis FJ, Campbell IG, Brenton JD, Bowtell DD, Benítez J, Pharoah PDP, Köbel M, Ramus SJ, Goode EL.

Mayo Clin Proc. 2018 Mar;93(3):307-320. doi: 10.1016/j.mayocp.2017.10.023.

50.

Analysis of response rate with ANTI PD1/PD-L1 monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trials.

Carretero-González A, Lora D, Ghanem I, Zugazagoitia J, Castellano D, Sepúlveda JM, López-Martin JA, Paz-Ares L, de Velasco G.

Oncotarget. 2018 Jan 20;9(9):8706-8715. doi: 10.18632/oncotarget.24283. eCollection 2018 Feb 2.

Supplemental Content

Loading ...
Support Center